Skip to content
Screener

Arrowhead Research ARWR Operating Cash Flow

Operating Cash Flow at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$792.82M-426%
ALN
Alnylam PharmaceuticalsALNY
$326.72M+113%
Assembly Biosciences logo
Assembly BiosciencesASMB
-$22.1M+5.7%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
-$8.11M+39.4%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$97M+11.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$128.51M-23.7%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemSix Months Ended March 31, 2026Six Months Ended March 31, 2025
Deferred revenue154,76043,268
Operating lease, net(2,423)(2,255)
Other3613,169
Net cash provided by operating activities97,923313,781
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment(4,713)(12,813)
Purchases of available-for-sale securities(1,061,577)(677,892)
Proceeds from sales of available-for-sale securities23,748

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's operating cash flow?
Arrowhead Research (ARWR) reported operating cash flow of $84.44M in Q1 2026.
How has Arrowhead Research's operating cash flow changed year-over-year?
Arrowhead Research's operating cash flow decreased by 81.6% year-over-year, from $460.05M to $84.44M.
What is the long-term trend for Arrowhead Research's operating cash flow?
Over 2 years (2022 to 2024), Arrowhead Research's operating cash flow has grown at a 84.4% compound annual growth rate (CAGR), from -$136.13M to -$462.85M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Arrowhead Research's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude